Clinical Trial Update: A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for a phase 1/2 study evaluating the efficacy and safety of Ivarmacitinib to prevent acute graft-versus-host disease after HLA-matched t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Ivarmacitinib

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: aGVHD | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING